This article is more than 5 years old. Information may no longer be current.

NICE recommends Eylea for myopic choroidal neovascularization

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The National Institute for Health and Care Excellence has given final positive recommendation for Eylea for the treatment of visual impairment due to myopic choroidal neovascularization, according to a Bayer press release.

In the phase 3 MYRROR study, Eylea (aflibercept) achieved “sustained and clinical meaningful visual improvements” over 48 weeks in patients with myopic CNV.

“We are pleased that NICE has recognized the value of Eylea and the benefits that it can bring to patients and the clinical community,” Lars Bruening, Bayer UK/Ireland CEO, said in the release. “At Bayer we are committed to ensuring all eligible patients have access to Eylea in line with the market authorization so it is great news for patients with [myopic] CNV in England and Wales who will have access to this effective treatment as soon as adopted by policy makers.”